January 13, 2012Open Access

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

Key Points

Key points are not available for this paper at this time.

Abstract

Not all mutant KRas proteins affect patient survival or downstream signaling in a similar way. The heterogeneous behavior of mutant KRas proteins implies that therapeutic interventions may need to take into account the specific mutant KRas expressed by the tumor.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Ihle et al. (Fri,) studied this question.

synapsesocial.com/papers/69db1d5937b5141e3ba3cd63 https://doi.org/https://doi.org/10.1093/jnci/djr523

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The BATTLE Trial: Personalizing Therapy for Lung Cancer2011 · 893 citations
2Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors.1991 · 212 citations
3Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival2010 · 351 citations
4Multiple Oncogenic Changes (<i>K-RASV12</i>, p53 Knockdown,<i>Mutant EGFRs, p16</i>Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial Cells2006 · 266 citations
5Prognostic value of specific KRAS mutations in lung adenocarcinomas.1997 · 78 citations

Bookmark

View Full Paper